The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans

Diabetes

Volumn 54, Issue 5, 2005, Pages 1364-1370

  Andrew, Ruth ^a   Westerbacka, Jukka ^b   Wahren, John ^c   Yki Järvinen, Hannele ^b   Walker, Brian E ^a,d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF HELSINKI   (Finland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTISONE; DEXAMETHASONE; FATTY ACID; GLUCOCORTICOID; HYDROCORTISONE;

ADIPOSE TISSUE; ADULT; ARTICLE; CLINICAL ARTICLE; CORTISOL SYNTHESIS; HEPATIC VEIN; HORMONE SYNTHESIS; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; LIVER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; OBESITY; PATHOPHYSIOLOGY; PORTAL VEIN; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW; STEADY STATE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSE TISSUE; ADULT; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; INSULIN RESISTANCE; KINETICS; LIVER; MALE; REFERENCE VALUES; SPLANCHNIC CIRCULATION; VISCERA;

EID: 17844363297     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.5.1364     Document Type: Article

References (38)

1. Seckl JR, Walker BR: 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific amplifier of glucocorticoid action (Review). Endocrinology 142: 1371-1376, 2001
2. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS: A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170, 2001
3. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS: Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 112:83-90, 2003
4. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ: Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A 101:7088-7093, 2004
5. Kotelevtsev YV, Holmes MC, Burchell A, Houston PM, Scholl D, Jamieson PM, Best R, Brown RW, Edwards CRW, Seckl JR, Mullins JJ: 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid inducible responses and resist hyperglycemia on obesity and stress. Proc Natl Acad Sci U S A 94:14924-14929, 1997
6. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, Seckl JR: Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276:41293-41300, 2001
7. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR: Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1 deficient mice. Diabetes 53:931-938, 2004
8. Livingstone DEW, Jones GC, Smith K, Andrew R, Kenyon CJ, Walker BR: Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141:560-563, 2000
9. Liu Y, Nakagawa Y, Wang Y, Li R, Li X, Ohzeki T, Friedman TC: Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes 52:1409-1416, 2003
10. Stewart PM, Boulton A, Kumar S, Clark PMS, Shackleton CHL: Cortisol metabolism in human obesity: impaired cortisone-cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84:1022-1027, 1999
11. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DEW, Johnson O, Walker BR: Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86:1418-1421, 2001
12. Rask E, Walker BR, Soderberg S, Livingstone DEW, Eliasson M, Johnson O, Andrew R, Olsson T: Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87:3330-3336, 2002
13. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi M-C, Grino M: Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 87:2701-2705, 2002
14. Lindsay RS, Tataranni A, Permana P, Livingstone DEW, Wake DJ, Walker BR: Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and mRNA levels are associated with adiposity and insulinaemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 88:2738-2744, 2003
15. Wake DJ, Rask E, Livingstone DEW, Soderberg S, Olsson T, Walker BR: Local and systemic impact of transcriptional upregulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 88:2983-2988, 2003
16. Engeli S, Bohnke J, Fetdpausch M, Gorzelniak K, Heintze U, Janke J, Luft FC, Sharma AM: Regulation of 11β-hydroxysteroid dehydrogenase genes in human adipose tissue: influence of central obesity arid weight loss. Obesity Research 12:9-17, 2004
17. Kannisto K, Pietilainen KH, Ehrenborg E, Rissanen A, Kaprio J, Hamsten A, Yki-Jarvinen H: Overexpression of 11beta-hydroxy steroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab 89:4414-4421, 2004
18. Sandeep TC, Andrew R, Homer NZM, Andrews RC, Smith K, Walker BR: Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 54:872-879, 2005
19. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CRW: Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 80:3155-3159, 1995
20. Andrews RC, Rooyackers O, Walker BR: Effects of the 11beta-hydroxy steroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 88:285-291, 2003
21. Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, Ronquist-Nii Y, Ohman B, Abrahmsen L: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45:1528-1532, 2002
22. Alberts P, Nilsson C, Selen G, Engblom NHM, Norlin S, Klingstrom G, Larsson C, Forsgren M, Ashkzan M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Bjorkstrand E, Abrahmsen LB: Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycaemic mice strains. Endocrinology 144:4755-4762, 2003
23. Bujalska IJ, Walker EA, Hewison M, Stewart PM: A switch in dehydrogenase to reductase activity of 11beta-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 87:1205-1210, 2002
24. Walker BR, Campbell JC, Fraser R, Stewart PM, Edwards CRW: Mineralocorticoid excess and inhibition of 11β-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf) 27:483-492, 1992
25. Basu R, Singh RJ, Basu A, Chittilapilly EG, Johnson CM, Toffolo G, Cobelli C, Rizza RA: Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-β hydroxysteroid dehydrogenase type 1 pathway. Diabetes 53:2051-2059, 2004
26. Bujalska IJ, Kumar S, Stewart, PM: Does central obesity reflect "Cushing's disease of the omentum"? Lancet 349:1210-1213, 1997
27. Aldhahi W, Mun E, Goldfine AB: Portal and peripheral cortisol levels in obese humans. Diabetologia 47:833-836, 2004
28. Katz JR, Mohamed-Ali V, Wood PJ, Yudkin JS, Coppack SW: An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. Clin Endocrinol 50:63-68, 1999
29. Andrew R, Smith K, Jones GC, Walker BR: Distinguishing the activities of 11β-hydroxysteroid dehydrogenases in vivo using isotopically labelled cortisol. J Clin Endocrinol Metab 87:277-285, 2002
30. 2 uptake and blood flow. Am J Physiol 271:E406-E504, 1996
31. Gastaldelli A, Coggan AR, Wolfe RR: Assessment of methods for improving tracer estimation of non-steady-state rate of appearance. J Appl Physiol 87:1813-1822, 1999
32. Best R, Nelson SM, Walker BR: Dexamethasone and 11-dehydrodexamethasone as tools to investigate the isozymes of 11β-hydroxysteroid dehydrogenase in vitro and in vivo. J Endocrinol 153:41-48, 1997
33. Shafqat N, Elleby B, Svensson S, Shafqat J, Jornvall H, Abrahmsen L, Oppermann U: Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from glucocorticoid resistant (guinea pig) versus sensitive (human) species. J Biol Chem 278:2030-2035, 2003
34. Bush IE: 11β-hydroxysteroid dehydrogenase: contrast between studies in vivo and studies in vitro. Adv Biosci 3:23-39, 1969
35. Jamieson PM, Walker BR, Chapman KE, Rossiter S, Seckl JR: 11β-Hydroxysteroid dehydrogenase type 1 is a predominant 11-reductase in the intact perfused rat liver. J Endocrinol 175:680-692, 2000
36. Stewart PM, Wallace AM, Atherden SM, Shearing CH, Edwards CRW: Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11β-hydroxysteroid dehydrogenase activity in man. Clin Sci 78:49-54, 1990
37. Tomlinson JW, Moore JS, Clark PMS, Holder G, Shakespeare L, Stewart PM: Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. J Clin Endocrinol Metab 89:2711-2716, 2004
38. Jamieson A, Wallace AM, Walker BR, Andrew R, Fraser R, White PC, Connell JMC: Apparent cortisone reductase deficiency: a functional defect in 11β-hydroxysteroid dehydrogenase type 1. J Clin Endocrinol Metab 84:3570-3574, 1999